Medicare Coverage Established for the Oncotype DX AR-V7 Nucleus Detect Test in Patients with Advanced Prostate Cancer

Share this article

Medicare Covers the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Patients with Access to More Definitive Answers

Medicare will begin covering the Oncotype DX AR-V7 Nucleus Detect® Test for metastatic castration-resistant prostate cancer (mCRPC) patients throughout the United States starting December 10. The test addresses a major challenge facing patients with metastatic castration-resistant prostate cancer (mCRPC) – how to select the right treatment at the right time over the course of their disease.

The Oncotype DX AR-V7 Nucleus Detect Test is the first and only nuclear-localized AR-V7 test that can help guide treatment decisions by identifying mCRPC patients who may benefit from continued androgen receptor (AR)-targeted drugs, such as XTANDI® (enzalutamide) or ZYTIGA® (abiraterone) and ERLEADA™ (apalutamide), as well as those who have become resistant to AR-targeted drugs and should instead switch to chemotherapy or other therapies. Now through Medicare, an estimated 25,000 mCRPC patients can now benefit from knowing their AR-V7 status to help select their treatment.

We are pleased so many advocates, patients and physicians voiced their support for Medicare for this kind of breakthrough technology to be made available to mCRPC patients. We look forward to continuing working with all of you to educate patients and the prostate community about the importance and impact of this test.

Oncotype DX My Colon Cancer Coach